CanBas Co

CanBas Co Assets per Share

The Total Assets per Share of CanBas Co (4575.T) as of Oct 19, 2026 is 90.14 JPY. In the previous year, Total Assets per Share was 154.74 JPY — a change of -41.75% (lower).

Assets per Share

90.14JPY

YoY

-41.75%

Last updated:

Total Assets per Share of CanBas Co is 2026 90.14 JPY. Total Assets per Share of CanBas Co was 2025 154.74 JPY. It decreases by -41.75% lower compared to the previous year.

The CanBas Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2019
44.41 JPY
Jan 1, 2020
64.09 JPY
Jan 1, 2021
65.73 JPY
Jan 1, 2022
40.12 JPY
Jan 1, 2023
105.83 JPY
Jan 1, 2024
123.43 JPY
Jan 1, 2025
154.74 JPY
Jan 1, 2026
90.14 JPY
The CanBas Co Assets per Share history
YEARAssets per ShareYoY
90.14JPY-41.75%
154.74JPY+25.37%
123.43JPY+16.63%
105.83JPY+163.81%
40.12JPY-38.97%
65.73JPY+2.56%
64.09JPY+44.31%
44.41JPY+51.37%
29.34JPY-41.78%
50.39JPY+2.69%
49.08JPY-3.07%
50.63JPY+151.05%
20.17JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Total Assets per Share of CanBas Co is 90.14 JPY in 2026.

Total Assets per Share of CanBas Co changed from 154.74 JPY to 90.14 JPY, representing a -41.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — CanBas Co

All Key Metrics — CanBas Co